Trending...
- Mayor Brandon Johnson, City Of Chicago Win Court Order Restoring Federal Shelter And Services Program
- Powering the Next Frontier of the $1 Trillion Space Economy: Ascent Solar Technologies (N A S D A Q: ASTI)
- Dr. Jay A. Johannigman Delivers Lecture at the John R. Border Memorial Lectureship in Buffalo
NORTHFIELD, Ill. ~ NORTHFIELD, Ill.-- The College of American Pathologists (CAP) has recently released an updated version of their "Principles of Analytic Validation of Immunohistochemical Assays" guideline. This update aims to improve the precision and accuracy of clinical immunohistochemical assays by assessing new evidence published since the original guideline was released in 2014.
According to Jeffrey D. Goldsmith, MD, FCAP, chair of the guideline, this update is crucial as immunohistochemical assays often play a significant role in guiding therapeutic decisions for cancer treatment. The revised guideline provides new and revised recommendations for the analytic validation and verification of these assays, with a particular focus on predictive markers.
While many of the original statements from the 2014 guideline remain similar, there are several new recommendations that provide guidance for validating immunohistochemical assays performed on cytology specimens and predictive marker assays with distinct scoring systems. For initial analytic validation or verification of any assay used clinically, laboratories should aim for at least 90% overall concordance between the new assay and the comparator assay or expected results.
More on illi News
This updated guideline also applies to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) IHC performed on breast carcinoma. These markers should also be validated at a minimum concordance rate of 90%, replacing the previously different thresholds. This recommendation aims to harmonize validation requirements for all immunohistochemical markers.
Dr. Goldsmith emphasizes that although there were no significant new findings in the systematic review conducted for this update, the numerical considerations and modeling discussed in the original document are still relevant. If unexpected results are obtained during validation or verification, it is recommended that laboratories investigate the causes with their immunohistochemistry medical director.
The updated guideline also includes a strong recommendation for predictive marker assays such as HER2 and programmed death receptor-1 (PD-L1), where more than one scoring system is used. In these cases, separate validation or verification should be performed based on the antibody clone and scoring system combination.
More on illi News
Specific guidance for validating immunohistochemistry performed on cytology specimens is also provided in the updated guideline. These recommendations are now available in an early online release in the Archives of Pathology & Laboratory Medicine and were established through the assessment of evidence published since the original guideline was released.
The CAP has made tools, resources, and information for this updated guideline available on their website, cap.org. This will help laboratories adhere to the "Principles of Analytic Validation of Immunohistochemical Assays" and ensure increased precision and accuracy of clinical immunohistochemical assays.
According to Jeffrey D. Goldsmith, MD, FCAP, chair of the guideline, this update is crucial as immunohistochemical assays often play a significant role in guiding therapeutic decisions for cancer treatment. The revised guideline provides new and revised recommendations for the analytic validation and verification of these assays, with a particular focus on predictive markers.
While many of the original statements from the 2014 guideline remain similar, there are several new recommendations that provide guidance for validating immunohistochemical assays performed on cytology specimens and predictive marker assays with distinct scoring systems. For initial analytic validation or verification of any assay used clinically, laboratories should aim for at least 90% overall concordance between the new assay and the comparator assay or expected results.
More on illi News
- Chicago: Mayor Brandon Johnson Testifies On Trump Administration's Immigration Raids, SNAP Cuts Before United Nations Human Rights Council
- Local Lighting Experts Debut AI Christmas Decorator: Upload a Photo, Get Instant Professional Holiday Design-- Completely Free
- Surf Air Mobility (N Y S E: SRFM) Accelerates Regional Air Mobility Revolution with Electra Aero Partnership, Palantir Alliance, and Record Revenue
- Cybersecurity is Fast Becoming a Vital Issue for Protecting Personal Information and Portfolio Wealth
- 10 Essential Tips for Maximizing Value When Choosing Your Orlando Wedding Venue
This updated guideline also applies to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) IHC performed on breast carcinoma. These markers should also be validated at a minimum concordance rate of 90%, replacing the previously different thresholds. This recommendation aims to harmonize validation requirements for all immunohistochemical markers.
Dr. Goldsmith emphasizes that although there were no significant new findings in the systematic review conducted for this update, the numerical considerations and modeling discussed in the original document are still relevant. If unexpected results are obtained during validation or verification, it is recommended that laboratories investigate the causes with their immunohistochemistry medical director.
The updated guideline also includes a strong recommendation for predictive marker assays such as HER2 and programmed death receptor-1 (PD-L1), where more than one scoring system is used. In these cases, separate validation or verification should be performed based on the antibody clone and scoring system combination.
More on illi News
- Americans Are Trading Offices for Beaches: How Business Ownership Enables the Ultimate Location Freedom
- Boston Industrial Solutions' Natron® DC Series Ink Has Had an Upgrade!
- Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament
- Jacob Emrani Nominated for LA Executive Award
- XP Launches Ticket Buyback Solution to Help Fans Sell Tickets Easily and Securely
Specific guidance for validating immunohistochemistry performed on cytology specimens is also provided in the updated guideline. These recommendations are now available in an early online release in the Archives of Pathology & Laboratory Medicine and were established through the assessment of evidence published since the original guideline was released.
The CAP has made tools, resources, and information for this updated guideline available on their website, cap.org. This will help laboratories adhere to the "Principles of Analytic Validation of Immunohistochemical Assays" and ensure increased precision and accuracy of clinical immunohistochemical assays.
Filed Under: Business
0 Comments
Latest on illi News
- Lawproactive Launches Next-Generation CRM, Marrying Data and Location with Geo-Optimized Funnels for Attorney Lead Generation
- POWER SOLUTIONS N.V. Partners with ENERGY33 LLC to Deliver a 40.5 MW Temporary Power Project for ECUACORRIENTE S.A. in Ecuador
- Axis International Invites Inventors to Turn Ideas Into Market-Ready Products
- Pioneering the Future of Human-Computer Interaction Through AI-Powered Neural Input Technology: Wearable Devices Ltd. (N A S D A Q: WLDS)
- Isringhausen Imports Named Best Auto Dealer — Again
- Epic Pictures Group Sets North American Release Date for the Action Thriller LOST HORIZON
- HR Soul Consulting Recognized as a 2025 Inc. Power Partner Award Winner for the Fourth Consecutive Year
- Due Date Performance Matters. Especially Dealing with Suppliers
- Industrial Steam Install at Crider Foods Facility
- Collinwood Technology Partners Launches Salesforce Practice, Appoints Karthik Jayaraman as Founding Leader
- Brazil 021 Chicago Launches New Website and Expands with No-Gi Classes for All Levels
- American Star Guard Unveils a Powerful Rebrand and Expanded Security Services Throughout Nevada
- Green Valley Manufacturing of Decatur, IL, acquires Benda Conveyor Systems of Tinley Park, IL
- PlaceBased Media Expands Point-of-Care Advertising Inventory Across U.S. Clinic Network
- Flexible Plan Investments launches FlexDirex, a first-to-market suite of single-stock ETF strategies in the U.S
- Mayor Brandon Johnson, City Of Chicago Win Court Order Restoring Federal Shelter And Services Program
- Mayor Brandon Johnson And The Chicago Department Of Business And Consumer Protection Launch Campaign To Celebrate Neighborhood Businesses Ahead Of Holiday Season
- Inktavo Awards Winners Announced at Print Hustlers Conference 2025
- Chicago: Weekend Recap: Mayor Brandon Johnson Walks For Homelessness Awareness, Joins 17th Ward Residents For Community Meeting, Affirms Support For Food Pantries, Welcomes Rugby's Most Storied National Teams To Soldier Field
- Revenue Optics Ignites AI Revolution in Industrial Distribution